[ad_1]
What happened
One of the most popular coronavirus stocks, Modern (NASDAQ: mRNA), was struggling on Monday. Although it did not decrease as much as the S&P 500 index, Moderna was still down nearly 2% at the end of the afternoon. The positive news from a big rival was one of the main reasons why.
So what
It almost goes without saying now that this rival – indeed, rivals – is the combination of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). After all, Moderna and Pfizer / BioNTech are the developers of the two main coronavirus vaccines currently circulating around the world.
Image source: Getty Images.
On Monday morning, Pfizer and BioNTech announced the results of a Phase 2/3 trial measuring the effectiveness of their Comirnaty vaccine in children aged 5 to 11. tolerated with side effects similar to those of people 16 to 25 years old who have already received the injections.
Now what
Pfizer and BioNTech waste no time with Comirnaty. The two companies said they intend to share data from the new trial with the FDA, the European Medicines Agency which regulates the 27-member European Union and other regulatory authorities around the world “as soon as as possible”. They will also file an emergency use authorization for this demographic with the FDA.
Moderna’s efforts with this age cohort continue. The biotech company launched the Phase 2/3 KidCOVE trial in March, aimed at testing its 1273 mRNA in children aged 6 months to just under 12 years old.
This article represents the opinion of the author, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are heterogeneous! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.
[ad_2]
Source link